Kalaris Therapeutics Inc (KLRS) — Analyst outlook / Analyst consensus target is.
The consensus price target is $21.00 (low: $19.00, high: $23.00), representing an upside of 257.8% from the current price $5.87.
Analysts estimate Earnings Per Share (EPS) of $-9.66 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-11.73 vs est $-9.66 (missed -21.4%). 2025: actual $-2.85 vs est $-3.38 (beat +15.7%). Analyst accuracy: 82%.
KLRS Stock — 12-Month Price Forecast
$21.00
▲ +257.75% Upside
Average Price Target
Based on 0 Wall Street analysts offering 12-month price targets for Kalaris Therapeutics Inc, the average price target is $21.00, with a high forecast of $23.00, and a low forecast of $19.00.
The average price target represents a +257.75% change from the last price of $5.87.
Highest Price Target
$23.00
Average Price Target
$21.00
Lowest Price Target
$19.00
EPS Estimates — KLRS
82%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$11.73
vs Est –$9.66
▼ 17.6% off
2025
Actual –$2.85
vs Est –$3.38
▲ 18.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — KLRS
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
